• Conditions and diseases

  • Blood and immune system •
  • Cancer •
  • Cardiovascular •
  • Central nervous system •
  • Digestive system •
  • Ear and nose •
  • Endocrine, nutritional and metabolic •
  • Eye •
  • Gynaecology, pregnancy and birth •
  • Infectious diseases •
  • Injuries, accidents and wounds •
  • Mental health and behavioural conditions •
  • Mouth and dental •
  • Musculoskeletal •
  • Respiratory •
  • Skin •
  • Urogenital

• Public health

  • Accidents and injuries •
  • Alcohol •
  • Behaviour change •
  • Cancer •
  • Cardiovascular disease •
  • Child health •
  • Child social care •
  • Chronic illness •
  • Diabetes •
  • Drugs •
  • Environmental health •
  • Infectious diseases •
  • Maternal health •
  • Mental health •
  • Non-communicable diseases •
  • Obesity and diet •
  • Occupational health •
  • Older people •
  • Physical activity •
  • Sexual health •
  • Smoking and tobacco •
  • Transport •
  • Vaccine preventable diseases •
  • Working with and involving communities

• Treatments, Procedures and Devices

  • Bones and joint surgery •
  • Cardiovascular surgery •
  • Cardiovascular system drug treatments •
  • Clinical devices •
  • Diagnostic imaging •
  • Diagnostic procedures •
  • Digestive tract and other abdominal organs surgery •
  • Drug treatments •
  • Endocrine system and breast surgery •
  • Eye surgery •
  • Nervous system surgery •
  • Radiotherapy •
  • Screening •
  • Surgical procedures •
  • Therapeutic procedures •
  • Tissue and organ donation •
  • Urogenital surgery

• Guidance by type

  • Clinical Guidelines •
  • Technology appraisals •
  • Public health guidance •
  • Diagnostics guidance •
  • Interventional procedures guidance •
  • Medical technologies guidance •
  • Cancer service guidance •
  • Quality standards

• Guidance by date

  • View the guidance by date published

About NICE guidance Close

Navigation

• NICE guidance

• Find guidance
• NICE Pathways
• Latest guidance
• Guidance by type
• Guidance in development
• How guidance is produced
• NICE guidance research recommendations
• Guidance for patients and public
• Other publications
• Patient safety solutions pilot
• Quality standards

Everolimus for the second-line treatment of advanced renal cell carcinoma

Everolimus for the treatment of advanced and/or metastatic renal cell carcinoma

Status:	History
Expected date of issue:	August 2010
Referral date:	November 2008
Wave:	CRS1
Process:	STA
Notes: Cancer reform strategy batch 1
Topic area: Cancer Urogenital

Project team | Schedule | Stakeholders | Project history | Key documents

 

NICE project team

Executive Lead:	Peter Littlejohns
Technical Lead:	Helen Tucker
Communications manager:	Alice Law
Project manager:	Lori Farrar
Evidence review group:	Peninsula Technology Assessment Group (PenTAG)

Top

 

Provisional schedule

Closing date for invited submissions / evidence submission:	30 September 2009
1st appraisal committee meeting:	13 January 2010

Top

 

Consultees and commentators

Consultees Commentators (no right to submit or appeal) Manufacturers/sponsors Novartis (everolimus) Patient/carer groups James Whale Fund for Kidney Cancer Kidney Cancer UK Macmillan Cancer Support Rarer Cancers Forum Professional groups Royal College of Nursing Royal College of Physicians, Medical Oncology Joint Special Committee United Kingdom Oncology Nursing Society Others Department of Health Welsh Assembly Government General Department of Health, Social Services and Public Safety for Northern Ireland NHS Quality Improvement Scotland Comparator manufacturer(s) None Relevant research groups None Evidence review group National Institute for Health Research Health Technology Assessment Programme Peninsula Technology Assessment Group, University of Exeter (PenTAG) Associated guideline groups None Associated ublic health groups None

Top

 

Project history

Date Update 30 July 2010 This appraisal topic will be discussed at the 11 August 2010 appraisal committee meeting. During the appeal period for this appraisal, the manufacturer of everolimus (Novartis) submitted an amended dataset, which requires Committee consideration. 23 July 2010 Consultation on the final appraisal determination for this appraisal topic has been suspended. This will allow for the Appraisal Committee to consider new evidence submitted by Novartis on the total costs of use of everolimus in the NHS for the treatment of advanced renal cell cancer.  The timelines for this appraisal will be updated, when finalised.  20 August 2010 On 11 August 2010, the NICE Appraisal Committee met to consider new evidence submitted by Novartis on the total costs of use of everolimus in the NHS for the treatment of advanced renal cell cancer.  The Committee considered the relevance of the new information and agreed that it was important to consider it fully.  In order to do that, the Committee has asked the manufacturer to submit additional modelling data to clarify the uncertainty associated with the new evidence.The Committee will therefore continue consideration of this topic at  the earliest possible meeting time.  Exact timings are to be confirmed.

Top

 

Key documents

Everolimus for the second-line treatment of advanced renal cell carcinoma: EIA form 09 May 2011 Renal cell carcinoma (second line metastatic) - everolimus: appeal 21 December 2010 Renal cell carcinoma (second line metastatic) - everolimus: second final appraisal determination 26 November 2010 Renal cell carcinoma (second line metastatic) - everolimus: final appraisal determination 02 July 2010 Renal cell carcinoma (second line metastatic) - everolimus: statement on the delay for the current appraisal 08 April 2010 Renal cell carcinoma (second line metastatic) - everolimus: appraisal consultation document 09 February 2010 Everolimus for the treatment of advanced and/or metastatic renal cell carcinoma: final scope 12 August 2009 Everolimus for the treatment of advanced and/or metastatic renal cell carcinoma: institute's response to comments on the draft scope 12 August 2009 Everolimus for the treatment of advanced and/or metastatic renal cell carcinoma: institute's response to comments on the draft matrix 12 August 2009

This page was last updated: 09 May 2011